This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Can Established Pharmaceuticals Up Abbott (ABT) Q2 Earnings?
by Zacks Equity Research
According to Abbott (ABT), key emerging markets represent the most attractive long-term growth opportunities for its branded generics product portfolio within EPD.
Can Abbott (ABT) Rise on Robust Overall Growth in Q2 Earnings?
by Zacks Equity Research
Abbott (ABT) gains traction from a steady healthy growth trajectory seen in core Diabetes Care business.
Will Flagship Impella Drive Abiomed's (ABMD) Q1 Earnings?
by Zacks Equity Research
Abiomed's (ABMD) first-quarter fiscal 2019 earnings are likely to be driven by an exclusive Impella product line. Intense competition raises concern.
Can International Sales Drive Baxter's (BAX) Q2 Earnings?
by Zacks Equity Research
Baxter's (BAX) Q2 earnings likely to be aided by promising international ventures and acquisitions; cyclophosphamide competition raises concern.
Will Core Distribution Unit Aid McKesson (MCK) Q1 Earnings?
by Zacks Equity Research
Strong prospects in the Distribution Solutions segment is likely to boost McKesson's (MCK) top-line performance in the fiscal first quarter.
Will Core Segmental Growth Aid Stryker (SYK) in Q2 Earnings?
by Zacks Equity Research
Stryker's (SYK) strong segmental performance and acquisition-driven strategy are likely to drive Q2 earnings.
Should Value Investors Consider McKesson (MCK) Stock Now?
by Zacks Equity Research
Let's see if McKesson Corporation (MCK) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.
Amazon Forays Into Pharmacy Business: Red Alert for Others?
by Sweta Jaiswal
Amazon's entry into the high-potential pharmaceutical industry deals a blow to share prices of major players.
McKesson (MCK) Issues Strong Preliminary Results for Q1
by Zacks Equity Research
McKesson Corporation (MCK) declares solid preliminary results for Q1, courtesy of deals, divestitures and acquisitions.
Why Is McKesson (MCK) Up 1.7% Since Its Last Earnings Report?
by Zacks Equity Research
McKesson (MCK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
McKesson's (MCK) Q4 Earnings Miss Estimates, Sales Improve Y/Y
by Zacks Equity Research
McKesson (MCK) witnesses strong growth in its Distribution Solutions segment in Q4 of fiscal 2018.
Is McKesson Corporation (MCK) a Suitable Value Stock Now?
by Zacks Equity Research
Let's see if McKesson Corporation (MCK) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.
Top Stock Reports for Lockheed Martin, Mastercard & Colgate
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Lockheed Martin (LMT), Mastercard (MA) and Colgate (CL).
McKesson (MCK) Beats on Earnings and Sales in Q3
by Zacks Equity Research
McKesson Corporation (MCK) delivers strong performance on the back of solid organic growth.
McKesson (MCK) Beats on Earnings and Sales in Q2
by Zacks Equity Research
McKesson's adjusted earnings of $3.28 per share came above the Zacks Consensus Estimate of $2.78 and increased from $2.96 in the year-ago quarter.
Should You Buy McKesson Corporation (MCK) Ahead of Earnings?
by Zacks Equity Research
McKesson (MCK) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
Mckesson (MCK) to Report Q2 Earnings: A Beat in the Cards?
by Zacks Equity Research
McKesson Corporation (MCK) expects a strong second quarter owing to a gradually stabilizing generic and branded market.
Is McKesson (MCK) a Great Stock for Value Investors?
by Zacks Equity Research
Let's see if McKesson Corporation (MCK) stock is a good choice for value-oriented investors right now from multiple angles.
AmerisourceBergen's PharMEDium Slows Down, Competition Rife
by Zacks Equity Research
AmerisourceBergen Corporation (ABC) is facing immediate integration risks from its acquisition of PharMEDium. Also, competition in the generic space raise concern.
McKesson (MCK) Misses on Earnings and Sales in Q1
by Zacks Equity Research
McKesson???s adjusted earnings of $2.46 per share missed the Zacks Consensus Estimate of $2.81 and decreased from $3.15 in the year-ago quarter.
AmerisourceBergen's PharMEDium Slows Down, Competition Rife
by Zacks Equity Research
On Jul 10, we issued an updated research report on Chesterbrook, PA-based AmerisourceBergen Corporation (ABC).
Should Value Investors Consider McKesson (MCK) Stock?
by Zacks Equity Research
Value investing is easily one of the most popular ways to find great stocks in any market environment.
Why Is McKesson (MCK) Up 13% Since the Last Earnings Report?
by Zacks Equity Research
McKesson (MCK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
McKesson (MCK) Up 7.5% Since Earnings Report: Can It Continue?
by Zacks Equity Research
McKesson (MCK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
McKesson Corporation: Should Value Investors Pick this Stock?
by Zacks Equity Research
Value investing is easily one of the most popular ways to find great stocks in any market environment.